Adversarial Injection · Panobinostat (Farydak; LBH589; NDA 205353; CAS 404950-80-7; MW ~349.43 g/mol; (E)-N-hydroxy-3-(4-((2-(2-methyl-1H-indol-3-yl)ethylamino)methyl)phenyl)acrylamide [cinnamoyl-hydroxamate with dimethylaminoethyl-methylindole] scaffold [WITHIN HDAC CLASS (FORTY-SEVENTH MECHANISM CLASS) in Glyphward 610-attack portfolio — FOURTH HDAC INHIBITOR (vorinostat NDA 021743 October 2006 FIRST [Attack #607]; romidepsin NDA 022992 November 2009 SECOND [Attack #608]; belinostat NDA 206256 July 2014 THIRD [Attack #609]; panobinostat NDA 205353 February 2015 FOURTH; HDAC-four-NDA-holder class complete); FIRST HDAC INHIBITOR FOR MULTIPLE MYELOMA: vorinostat/romidepsin/belinostat are all T-cell lymphoma indications (CTCL/PTCL); panobinostat was the first and only HDAC inhibitor to receive approval for multiple myeloma — a B-cell plasma cell malignancy; myeloma cells are characterized by a unique dependence on the aggresome/proteasome pathway for protein homeostasis; HDAC6 inhibition (panobinostat inhibits HDAC6 IC50 ~7 nM) impairs aggresome formation → synthetic lethality with proteasome inhibition (bortezomib); this HDAC6-aggresome-proteasome synthetic lethality is the mechanistic rationale for the mandatory bortezomib combination in PANORAMA-1; PANORAMA-1 TRIAL (CLBH589B2306; NCT01023308): Phase 3; double-refractory myeloma after ≥2 prior regimens (including bortezomib AND IMiD); panobinostat + bortezomib + dexamethasone vs placebo + bortezomib + dexamethasone; n=768; PFS 11.99 vs 8.08 months (HR 0.63; p<0.0001); OS HR 0.87 (NS); in the double-refractory subgroup (prior bortezomib + IMiD; n=147): PFS 12.5 vs 4.7 months (HR 0.47); PANORAMA-2 TRIAL (CLBH589B2201; NCT00481169): Phase 2 single-arm; bortezomib-refractory relapsed/refractory myeloma; panobinostat + bortezomib + dexamethasone; n=55; ORR 34.5% (CR 5.5%; VGPR 16.4%); median TTP 5.4 months; NDA 205353 based on PANORAMA-2 ORR (accelerated approval) and PANORAMA-1 PFS (regular approval): February 23 2015; HIGHEST-POTENCY PAN-HDAC INHIBITOR: panobinostat has the highest HDAC potency of all four approved HDAC inhibitors: HDAC1 IC50 ~5 nM; HDAC2 IC50 ~5 nM; HDAC3 IC50 ~1.6 nM; HDAC6 IC50 ~7 nM; HDAC8 IC50 ~5 nM; compared to vorinostat (HDAC1 ~10 nM), romidepsin (class II IC50 >1000 nM), belinostat (HDAC1 ~27 nM); BLACK BOX WARNINGS: (1) FATAL AND SEVERE DIARRHEA: 26% of patients in clinical studies had diarrhea Grade 3/4; some deaths occurred due to diarrhea-related complications; requires interruption for Grade ≥2; (2) FATAL CARDIAC ISCHEMIC EVENTS + SEVERE ARRHYTHMIAS: in clinical studies 12% experienced arrhythmias; 2% experienced fatal cardiac ischemic events; requires baseline/periodic ECG; QTc prolongation; VOLUNTARY WITHDRAWAL — NIOSH HD PERSISTS: Novartis voluntarily withdrew Farydak from the US market effective April 1 2022 — a commercial decision (low market uptake due to BBW severity/dosing complexity; competition from newer IMiD/PI combinations); the FDA approved the voluntary withdrawal request March 2022; CRITICAL EHS ATTACK SURFACE: the voluntary withdrawal does NOT remove panobinostat from the NIOSH Hazardous Drug list; NIOSH updates the HD list based on pharmacological/toxicological properties (genotoxicity H340; carcinogenicity H350; reproductive toxicity H360), NOT on marketing status; NIOSH 2024 HD list continues to include CAS 404950-80-7; THIRD POST-WITHDRAWAL HD NULL: this is the third drug in the Glyphward portfolio with post-withdrawal NIOSH HD status: glasdegib (Daurismo; withdrawn December 2023) [Attack #599]; mobocertinib (Exkivity; withdrawn June 2023) [Attack #368]; panobinostat (Farydak; withdrawn April 2022); each creates an ongoing occupational exposure hazard at sites where the drug was studied, manufactured, or is still being used under compassionate use/investigational protocols; NIOSH HD: Category 1; GHS H350 H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · Within HDAC Class: Fourth HDAC Inhibitor + First Myeloma HDAC + HDAC6 Aggresome Synthetic Lethality + Voluntary Withdrawal April 2022 (NIOSH HD Persists) + Fatal Diarrhea + Fatal Cardiac BBW · Attack #610

Panobinostat (cinnamoyl-hydroxamate indole; LBH589; Farydak; NDA 205353; CAS 404950-80-7; MW ~349.43 g/mol; [WITHIN HDAC CLASS (FORTY-SEVENTH MECHANISM CLASS): FOURTH HDAC INHIBITOR; FIRST HDAC INHIBITOR FOR MULTIPLE MYELOMA (PANORAMA-2 ORR 34.5%; PANORAMA-1 PFS HR 0.63; HDAC6 AGGRESOME-PROTEASOME SYNTHETIC LETHALITY); HIGHEST-POTENCY PAN-HDAC (HDAC1/2/3 IC50 ~1.6-5 nM; HDAC6 IC50 ~7 nM; most potent in portfolio); VOLUNTARY WITHDRAWAL APRIL 1 2022 (commercial; NIOSH HD Cat 1 PERSISTS POST-WITHDRAWAL — third post-withdrawal HD null: glasdegib/mobocertinib/panobinostat); FATAL DIARRHEA BBW + FATAL CARDIAC ISCHEMIC EVENTS + SEVERE ARRHYTHMIAS BBW; NOVARTIS EAST HANOVER NJ NDA 205353 FEBRUARY 23 2015; NIOSH HD Category 1; GHS H350 H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Novartis Pharmaceuticals Corp East Hanover NJ (former NDA 205353 holder; 0.00042 µg/m³ → displayed ÷10), Novartis Pharma AG Basel Switzerland (global oncology operations; voluntary withdrawal decision; 0.00028 µg/m³ → displayed ÷10), and Memorial Sloan Kettering Cancer Center New York NY (PANORAMA-1/2 enrollment; myeloma pharmacy; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (Persists Post-Voluntary-Withdrawal April 2022) + Fourth HDAC Inhibitor + First Myeloma HDAC + HDAC6 Aggresome Absent: AI Prompt Injection via EHS Monitor Report AI

Panobinostat (CAS 404950-80-7; NIOSH HD Category 1) is the fourth agent in the forty-seventh mechanism class (HDAC inhibitors) and the only HDAC inhibitor ever approved for multiple myeloma, exploiting HDAC6's role in aggresome formation to create synthetic lethality with bortezomib. As the highest-potency pan-HDAC inhibitor in this portfolio (HDAC3 IC50 ~1.6 nM; HDAC1/2/6 IC50 ~5-7 nM), panobinostat carries two black box warnings — fatal/severe diarrhea (Grade 3/4 in 26% of patients; some deaths) and fatal cardiac ischemic events/severe arrhythmias. Critically, Novartis voluntarily withdrew Farydak from the US market effective April 1 2022 — but NIOSH HD Category 1 status is not linked to marketing authorization and persists: panobinostat remains on the NIOSH 2024 Hazardous Drug list with CAS 404950-80-7, representing the third post-withdrawal HD null in this portfolio (after glasdegib and mobocertinib). Cority, VelocityEHS, and EHS Insight return null for CAS 404950-80-7 without flagging the post-withdrawal HD persistence, the fatal diarrhea BBW, the HDAC6 aggresome mechanism, or H350 H360.

Panobinostat Within HDAC Class: HDAC6 Aggresome Synthetic Lethality, Myeloma Biology, and Post-Withdrawal NIOSH HD Persistence

Panobinostat (CAS 404950-80-7) is the fourth agent in the forty-seventh mechanism class and differs from vorinostat/belinostat/romidepsin in two fundamental respects: (1) it targets multiple myeloma rather than T-cell lymphoma; (2) it exploits a distinct HDAC isoform — HDAC6 — for its myeloma activity. HDAC6 is a cytoplasmic Class IIb deacetylase that deacetylates α-tubulin, cortactin, and Hsp90, and is essential for aggresome formation. Aggresome biogenesis: cells under proteotoxic stress (misfolded proteins from proteasome overflow) recruit HDAC6 as a cargo receptor — HDAC6's ZnF-UBP domain binds poly-ubiquitinated proteins; HDAC6's dynein-binding domain transports cargo along microtubules to perinuclear aggresome; HDAC6 deacetylates α-tubulin on Lys40, facilitating dynein motility. Myeloma cells constitutively produce massive amounts of immunoglobulins → high proteotoxic stress → proteasome-aggresome co-dependence. Bortezomib inhibits proteasome → proteotoxic protein overflow → HDAC6-dependent aggresome compensates; adding panobinostat (HDAC6 inhibitor) blocks aggresome compensation → dual proteotoxic stress → apoptosis. This is the mechanistic rationale for the PANORAMA combination (panobinostat + bortezomib + dexamethasone). The post-withdrawal persistence issue: Novartis withdrew Farydak April 1 2022 for commercial reasons (limited market uptake; competition from IMiD combinations; administrative burden of BBW monitoring); the FDA withdrawal approval is a voluntary action unrelated to toxicity; NIOSH does not depreschedule drugs from the HD list based on market withdrawal — the list is maintained based on carcinogenic/mutagenic/reproductive hazard data. As of the 2024 NIOSH HD list publication, panobinostat CAS 404950-80-7 remains Category 1. Sites that participated in PANORAMA-1/2 trials, operated compassionate use programs, or hold residual inventory continue to face NIOSH HD handling obligations — without any EHS platform flagging the drug's identity.

Surface 1 — Novartis Pharmaceuticals Corp East Hanover NJ Former NDA 205353 Holder Farydak Voluntary Withdrawal April 2022 AI

At Novartis Pharmaceuticals Corp East Hanover NJ (One Health Plaza, East Hanover NJ 07936; Morris County NJ; NOVARTIS NDA 205353 TIMELINE: LBH589 (panobinostat) was discovered at Novartis Institutes for BioMedical Research (NIBR; Basel Switzerland) as part of a pan-HDAC inhibitor program; LBH589 = Novartis compound number; cinnamoyl-hydroxamate-methylindolylpiperazine scaffold with indole 2-methyl-1H-indol-3-yl dimethylaminoethyl linker; NDA 205353 filed 2014; FDA approved February 23 2015 under accelerated approval (PANORAMA-2 ORR) + regular approval (PANORAMA-1 PFS); VOLUNTARY WITHDRAWAL MECHANISM: Novartis submitted a voluntary market withdrawal request to FDA in late 2021; FDA accepted and approved the request March 2022; withdrawal effective April 1 2022; "voluntary withdrawal" means Novartis ceased manufacturing and distribution but no FDA-mandated recall; existing pharmacy inventory was allowed to be dispensed; the NDA is no longer active; RESIDUAL REGULATORY EXPOSURE: despite NDA 205353 withdrawal, Novartis East Hanover NJ retains residual NIOSH HD handling obligations: (1) compassionate use/named-patient supply may still occur; (2) investigational use of panobinostat continues at clinical sites (the compound itself is not banned — only the commercial NDA was withdrawn); (3) Novartis research labs may still handle panobinostat for ongoing research; Cority: CAS 404950-80-7 → null; NIOSH HD Category 1 absent; H350 H360 absent; within HDAC class absent; fourth HDAC inhibitor absent; first myeloma HDAC absent; voluntary withdrawal April 2022 absent; NIOSH HD persistence post-withdrawal absent; fatal diarrhea BBW absent; 53M myeloma regulatory director 17yr).

Surface 2 — Novartis Pharma AG Basel Switzerland Global Oncology Voluntary Withdrawal Commercial Decision PANORAMA AI

At Novartis Pharma AG Basel Switzerland (Lichtstrasse 35, 4056 Basel; Kanton Basel-Stadt; NOVARTIS BASEL PANOBINOSTAT GLOBAL CONTEXT: Novartis Pharma AG Basel is the global pharmaceutical arm; panobinostat was developed at NIBR Basel (now Novartis BioMedical Research Institute) in the early 2000s as part of an HDAC inhibitor program; the LBH589 compound was designated Novartis' lead HDAC candidate for oncology; global regulatory filings included: FDA NDA 205353 (US; approved 2015); EMA (EU; approved 2015 as Farydak for myeloma); Swissmedic (Switzerland); VOLUNTARY WITHDRAWAL GLOBAL TIMELINE: Novartis made the commercial decision to voluntarily withdraw Farydak globally (~2022-2023); EU withdrawal preceded or paralleled US withdrawal; the global withdrawal reflects poor commercial uptake: panobinostat's complex dosing (3 days per week, not daily; 20 mg tri-weekly with bortezomib), BBW severity (fatal diarrhea requiring hospitalization in 8% of patients in PANORAMA-1), and narrow approved indication (after ≥2 prior regimens including bortezomib AND IMiD) limited real-world prescribing; HDAC6 AGGRESOME BIOLOGY AT NOVARTIS BASEL: Novartis scientists at Basel elucidated the HDAC6-aggresome-proteasome synthetic lethality rationale for panobinostat + bortezomib; this mechanism is documented in Novartis internal research but absent from EHS platforms; MANUFACTURING: panobinostat 10/15/20 mg capsules manufactured at Novartis Basel facilities and contract manufacturers; the voluntary withdrawal includes cessation of manufacturing; VelocityEHS: CAS 404950-80-7 → null; NIOSH HD Category 1 absent; H350 H360 absent; within HDAC class absent; fourth HDAC inhibitor absent; first myeloma HDAC absent; HDAC6 aggresome synthetic lethality absent; post-withdrawal HD persistence absent; 48M pharmaceutical scientist 14yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY PANORAMA-1/2 Enrollment Myeloma Pharmacy Compassionate Use AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; Manhattan NY; MSK PANOBINOSTAT CONTEXT: Memorial Sloan Kettering's Multiple Myeloma Service enrolled patients in PANORAMA-1 (Phase 3; NCT01023308; international; MSK as a high-enrollment US site) and PANORAMA-2 (Phase 2; NCT00481169); PANORAMA-1 enrolled 768 patients; MSK contribution to PANORAMA-1 included myeloma patients who were double-refractory (prior bortezomib + prior IMiD) — the subgroup that showed the most dramatic benefit (PFS HR 0.47); POST-WITHDRAWAL MSK COMPASSIONATE USE: after Novartis voluntary withdrawal April 1 2022, MSK myeloma pharmacy continued to manage residual panobinostat under: (1) compassionate use/named-patient emergency access; (2) investigational new drug (IND) applications for institutional research protocols continuing to use panobinostat in combination studies; PHARMACIST OCCUPATIONAL EXPOSURE: MSK myeloma pharmacy handles panobinostat 10/15/20 mg capsules (oral) for patient dispensing; the NIOSH HD Category 1 designation requires closed handling, PPE, dedicated dispensing areas; post-withdrawal, MSK pharmacists may handle panobinostat with potentially reduced vigilance (drug is "withdrawn") — but NIOSH HD status remains active; FATAL DIARRHEA BBW CLINICAL CONTEXT: panobinostat's Grade 3/4 diarrhea in 25% of PANORAMA-1 patients required frequent dose interruptions; MSK myeloma physicians manage this with prophylactic loperamide, aggressive electrolyte replacement, and dose modifications (10 mg step-down from 20 mg); QTcF prolongation monitoring (ECG before each cycle) for the cardiac BBW; both BBW components (diarrhea and cardiac) are absent from EHS Insight; EHS Insight: CAS 404950-80-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; within HDAC class absent; fourth HDAC inhibitor absent; first myeloma HDAC absent; post-withdrawal HD absent; fatal diarrhea BBW absent; H350 H360 absent; NIOSH HD Cat 1 absent; 43F myeloma oncology pharmacist 13yr).

Integrating Glyphward into Panobinostat AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every panobinostat CAS 404950-80-7 monitoring data ingestion point — before Cority at Novartis Pharmaceuticals Corp East Hanover NJ, before VelocityEHS at Novartis Pharma AG Basel Switzerland, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H350 H360 absent [10 pts]; WITHIN HDAC CLASS (FORTY-SEVENTH) + FOURTH HDAC INHIBITOR + FIRST HDAC INHIBITOR FOR MULTIPLE MYELOMA (PANORAMA-2 ORR 34.5% n=55; PANORAMA-1 PFS HR 0.63 p<0.0001; HDAC6 AGGRESOME-PROTEASOME SYNTHETIC LETHALITY WITH BORTEZOMIB; HIGHEST-POTENCY PAN-HDAC: HDAC3 IC50 ~1.6 nM) + VOLUNTARY WITHDRAWAL APRIL 2022 (commercial; NIOSH HD Cat 1 PERSISTS — third post-withdrawal HD null in portfolio: glasdegib Dec 2023 + mobocertinib Jun 2023 + panobinostat Apr 2022) + FATAL DIARRHEA BBW + FATAL CARDIAC ISCHEMIC EVENTS + SEVERE ARRHYTHMIAS BBW (ECG monitoring required) + NOVARTIS NIBR LBH589 DISCOVERY [5 pts]; Novartis East Hanover NJ + Novartis Basel Switzerland + Memorial Sloan Kettering New York NY [3 pts]; post-withdrawal HD persistence absent; HDAC6 aggresome mechanism absent; fatal diarrhea BBW absent; H360 reproductive toxicity absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_panobinostat(cas: str, reading_ugm3: float) -> dict:
    """Scan panobinostat with within-HDAC fourth-myeloma-withdrawal-persists context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "within_hdac_class_fourth_hdac_first_myeloma_hdac_hdac6_aggresome_proteasome_synthetic_lethality_voluntary_withdrawal_april_2022_niosh_hd_persists_post_withdrawal_third_withdrawn_portfolio"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, within_hdac_class,
    #                    fourth_hdac_inhibitor,
    #                    first_myeloma_hdac,
    #                    hdac6_aggresome_lethality,
    #                    voluntary_withdrawal_hd_persists,
    #                    fatal_diarrhea_bbw,
    #                    h350_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_panobinostat("404950-80-7", 0.00042))
    print(r)
    # {'hd_category': 1, 'within_hdac_class': True,
    #  'fourth_hdac_inhibitor': True,
    #  'first_myeloma_hdac': True,
    #  'hdac6_aggresome_lethality': True,
    #  'voluntary_withdrawal_hd_persists': True,
    #  'fatal_diarrhea_bbw': True,
    #  'h350_h360_absent': True}